These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35416651)

  • 1. Pocket-to-Lead: Structure-Based
    Kojima E; Iimuro A; Nakajima M; Kinuta H; Asada N; Sako Y; Nakata Z; Uemura K; Arita S; Miki S; Wakasa-Morimoto C; Tachibana Y
    J Med Chem; 2022 Apr; 65(8):6157-6170. PubMed ID: 35416651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening.
    Yadav D; Paliwal S; Yadav R; Pal M; Pandey A
    PLoS One; 2012; 7(11):e48942. PubMed ID: 23145032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods.
    Wei Y; Li J; Chen Z; Wang F; Huang W; Hong Z; Lin J
    Eur J Med Chem; 2015 Aug; 101():409-18. PubMed ID: 26185005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting dynamic pockets of HIV-1 protease by structure-based computational screening for allosteric inhibitors.
    Kunze J; Todoroff N; Schneider P; Rodrigues T; Geppert T; Reisen F; Schreuder H; Saas J; Hessler G; Baringhaus KH; Schneider G
    J Chem Inf Model; 2014 Mar; 54(3):987-91. PubMed ID: 24528206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
    Qiu X; Zhao GD; Tang LQ; Liu ZP
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
    Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
    Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands.
    Zhu M; Du XN; Li YG; Zhang GN; Wang JX; Wang YC
    Bioorg Med Chem Lett; 2019 Feb; 29(3):357-361. PubMed ID: 30580917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of HIV-1 protease inhibitors with morpholine derivatives as P2 ligands in combination with cyclopropyl as P1' ligand.
    Dou Y; Zhu M; Dong B; Wang JX; Zhang GN; Zhang F; Wang YC
    Bioorg Med Chem Lett; 2020 Apr; 30(7):127019. PubMed ID: 32057582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
    Ghosh AK; Rao KV; Nyalapatla PR; Osswald HL; Martyr CD; Aoki M; Hayashi H; Agniswamy J; Wang YF; Bulut H; Das D; Weber IT; Mitsuya H
    J Med Chem; 2017 May; 60(10):4267-4278. PubMed ID: 28418652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.
    Perez MA; Fernandes PA; Ramos MJ
    J Mol Graph Model; 2007 Oct; 26(3):634-42. PubMed ID: 17459746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1' ligand to enhance binding with S1' subsite.
    Zhu M; Ma L; Dong B; Zhang G; Wang J; Zhou J; Cen S; Wang Y
    Bioorg Med Chem; 2020 Aug; 28(16):115623. PubMed ID: 32690263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase.
    Zhu M; Ma L; Wen J; Dong B; Wang Y; Wang Z; Zhou J; Zhang G; Wang J; Guo Y; Liang C; Cen S; Wang Y
    Eur J Med Chem; 2020 Jan; 186():111900. PubMed ID: 31771827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of HIV wild-type and mutant structures via in silico docking against diverse ligand libraries.
    Chang MW; Lindstrom W; Olson AJ; Belew RK
    J Chem Inf Model; 2007; 47(3):1258-62. PubMed ID: 17447753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LSTM-driven drug design using SELFIES for target-focused de novo generation of HIV-1 protease inhibitor candidates for AIDS treatment.
    Albrijawi MT; Alhajj R
    PLoS One; 2024; 19(6):e0303597. PubMed ID: 38905197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors.
    Ghosh AK; Krishnan K; Walters DE; Cho W; Cho H; Koo Y; Trevino J; Holland L; Buthod J
    Bioorg Med Chem Lett; 1998 Apr; 8(8):979-82. PubMed ID: 9871524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
    Arodola OA; Soliman ME
    Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
    Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.